COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases

Rahul S Dalal; Emma McClure; Jenna Marcus; Rachel W Winter; Matthew J Hamilton; Jessica R Allegretti

doi:10.1016/j.cgh.2021.02.004

COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol. 2021 Aug;19(8):1730-1732.e2. doi: 10.1016/j.cgh.2021.02.004. Epub 2021 Feb 4.

Authors

Rahul S Dalal¹, Emma McClure¹, Jenna Marcus¹, Rachel W Winter¹, Matthew J Hamilton¹, Jessica R Allegretti²

Affiliations

¹ Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: jallegretti@bwh.harvard.edu.

Abstract

Patients with inflammatory bowel disease (IBD) develop coronavirus disease 2019 (COVID-19) at similar rates as the general population, and there was initial concern regarding potential for severe illness.^1-4 Vaccinations were authorized for emergency use in the United States in December 2020 and aim to halt the spread of COVID-19. However, there are concerns that people will be hesitant to receive the vaccine for a variety of reasons including insufficient data in certain populations including those with IBD. We surveyed patients with IBD to identify potential concerns regarding COVID-19 vaccination.

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Inflammatory Bowel Diseases*
Perception
SARS-CoV-2
United States
Vaccination

Substances

COVID-19 Vaccines

Grants and funding

T32 DK007533/DK/NIDDK NIH HHS/United States